What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations across domestic and international markets, with a portfolio spanning branded generics, biosimilars and in-licensed drugs. In FY26 the business crossed $1 billion in revenue, growing 16.6% year-on-year, with domestic operations rising 10% and international operations 22%. Domestic sales run primarily through subsidiary Zuventus Healthcare, with restructuring affecting about 40% of the medical-representative force. International operations span Europe, Canada (through subsidiary Mantra Pharma) and other emerging markets. Three in-licensing deals expanded the portfolio: Novo Nordisk's rDNA semaglutide brand Poviztra, Sanofi's oral anti-diabetics Amaryl and Cetapin, and Roche's nephrology transplant drugs, supported by around 1,000 reps promoting Poviztra. Biologics subsidiary Gennova Biopharmaceuticals, now wholly owned after a Rs 2,318.7 million buyout of the remaining 12.05% stake, manufactures biosimilars including Elaxim, Vintor, Xgrast and Hamsyl. The largest cost line is raw materials at 18.4% of revenue; FY27 guidance targets low-to-mid-teen revenue growth and 75-100 bps EBITDA margin expansion.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from EMCURE PHARMACEUTICALS L's filed financials and exchange disclosures
EMCURE PHARMACEUTICALS L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol EMCURE.
Yes. Over the trailing twelve months EMCURE PHARMACEUTICALS L reported a net profit of ₹1,019 Cr on revenue of ₹9,683 Cr.
Yes. The dividend yield is 0.15% at the current price. It paid out 6% of its profit as dividend in FY26.
No. Debt stands at 0.24× equity, and it carries net debt of ₹1,067 Cr. That is lower than 37% of its 171 Pharmaceuticals peers.
On trailing P/E, EMCURE PHARMACEUTICALS L ranks 104 of 169 in Pharmaceuticals — cheaper than 39% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session EMCURE PHARMACEUTICALS L moves 1.20% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by EMCURE PHARMACEUTICALS L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
